AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14592846 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without vitamin E
Number of subjects: 16
Study 11724459 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain polyunsaturated fatty acids (LC-PUFA) supplementation in formulas for preterm infants
Number of subjects: 21
Study 11724459 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain polyunsaturated fatty acids (LC-PUFA) supplementation in formulas for term infants
Number of subjects: 21
Study 8557123 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-gauge needle
Number of subjects: 112
Study 8557123 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-gauge needle
Number of subjects: 112
Study 8557123 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-gauge needle
Number of subjects: 112
Study 1585856 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise testing (n = 50)
Number of subjects: 100
Study 1585856 — intervention group
Group type: COMPARATOR
Intervention: No exercise testing (n = 50)
Number of subjects: 100
Study 3903504 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg four times daily)
Number of subjects: 555
Study 3903504 — intervention group
Group type: COMPARATOR
Intervention: Sulfinpyrazone (200 mg four times daily)
Number of subjects: 555
Study 3903504 — intervention group
Group type: COMPARATOR
Intervention: Both aspirin and sulfinpyrazone
Number of subjects: 555
Study 31375148 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use advised between diagnosis and follow-up visit
Number of subjects: 0
Study 31375148 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 31375148 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use adherence (per-protocol analysis)
Number of subjects: 0
Study 31375148 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use
Number of subjects: 0
Study 29016878 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Monitoring (HM)
Number of subjects: 1339
Study 27505210 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based Attentional Bias Modification (ABM) training, 6 sessions over 2 weeks
Number of subjects: 434
Study 27505210 — intervention group
Group type: COMPARATOR
Intervention: Placebo training, 6 sessions over 2 weeks
Number of subjects: 434
Study 23586449 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (n = 48)
Number of subjects: 144
Study 23586449 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 48)
Number of subjects: 144
Study 23586449 — intervention group
Group type: COMPARATOR
Intervention: No Alcohol (n = 48)
Number of subjects: 144
Study 23586449 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher arousal with emotion suppression
Number of subjects: 144
Study 23167369 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus vinorelbine (NP) for 4 cycles
Number of subjects: 451
Study 23167369 — intervention group
Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 451
Study 20630944 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (160 mg/day)
Number of subjects: 12
Study 20630944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18312284 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 100
Study 18312284 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 100
Study 16210893 — intervention group
Group type: EXPERIMENTAL
Intervention: EBC collected using R Tube
Number of subjects: 23
Study 16210893 — intervention group
Group type: EXPERIMENTAL
Intervention: EBC collected using Ecoscreen with added resistance of 5 cm H2O (Res5)
Number of subjects: 23
Study 16210893 — intervention group
Group type: COMPARATOR
Intervention: EBC collected using Ecoscreen without added resistance
Number of subjects: 23
Study 16210893 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorine measurements
Number of subjects: 23
Study 12436150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg)
Number of subjects: 10
Study 10335245 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-length measurement technique
Number of subjects: 48
Study 10335245 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine measurement technique
Number of subjects: 48
Study 10335245 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-barrier measurement technique
Number of subjects: 48
Study 10335245 — intervention group
Group type: COMPARATOR
Intervention: All techniques
Number of subjects: 48
Study 8942407 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, low-fiber diet
Number of subjects: 43
Study 8251051 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine 3 to 8 g/day administered orally
Number of subjects: 0
Study 4022687 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution A (90 mmol/L sodium, 20 g/L glucose, bicarbonate)
Number of subjects: 140
Study 4022687 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution B (50 mmol/L sodium, 20 g/L glucose, citrate)
Number of subjects: 140
Study 4022687 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution C (30 mmol/L sodium, 20 g/L glucose, citrate)
Number of subjects: 140
Study 4022687 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution D (30 mmol/L sodium, 50 g/L glucose, citrate)
Number of subjects: 140
Study 31953863 — intervention group
Group type: EXPERIMENTAL
Intervention: daridorexant 5mg
Number of subjects: 359
Study 31953863 — intervention group
Group type: EXPERIMENTAL
Intervention: daridorexant 10mg
Number of subjects: 359
Study 31953863 — intervention group
Group type: EXPERIMENTAL
Intervention: daridorexant 25mg
Number of subjects: 359
Study 31953863 — intervention group
Group type: EXPERIMENTAL
Intervention: daridorexant 50mg
Number of subjects: 359
Study 31953863 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 359
Study 31953863 — intervention group
Group type: COMPARATOR
Intervention: zolpidem 10mg
Number of subjects: 359
Study 30056415 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability training (3 times/week for 8 weeks)
Number of subjects: 30
Study 30056415 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy program (Control group)
Number of subjects: 30
Study 29772132 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser beam on acupuncture points (low power infrared 980 nm, 50 mW laser, 30 seconds at 8,000 Hz, 10 sessions, 3 times per week)
Number of subjects: 0
Study 29772132 — intervention group
Group type: COMPARATOR
Intervention: Simulated laser acupuncture (laser off)
Number of subjects: 0
Study 24075527 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-controlled feedback (SELF) group
Number of subjects: 0
Study 24075527 — intervention group
Group type: COMPARATOR
Intervention: Clinician-controlled feedback (YOKED) group
Number of subjects: 0
Study 21537491 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive parathyroidectomy using surgical sonography (MIPUSS)
Number of subjects: 30
Study 21537491 — intervention group
Group type: COMPARATOR
Intervention: Conventional unilateral open procedure (OP)
Number of subjects: 30
Study 19528043 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-initiated tobacco control (ETC) consisting of on-site counselling plus up to four telephone booster sessions
Number of subjects: 1044
Study 19528043 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1044
Study 19528043 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC for unmotivated smokers
Number of subjects: 1044
Study 19528043 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC for ambivalent smokers
Number of subjects: 1044
Study 19528043 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC for motivated smokers
Number of subjects: 1044
Study 18389608 — intervention group
Group type: EXPERIMENTAL
Intervention: Curation algorithm for chronic gastritis after antihelicobacter therapy
Number of subjects: 0
Study 15107658 — intervention group
Group type: EXPERIMENTAL
Intervention: Montgomery‐Asberg Depression Rating Scale (MADRS)
Number of subjects: 139
Study 15107658 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Global Impressions Rating Scale for Severity (CGI‐S)
Number of subjects: 139
Study 15107658 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamilton Depression Rating Scale (HAM‐D)
Number of subjects: 139
Study 15107658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 11530993 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg LJP 394 weekly
Number of subjects: 19
Study 11530993 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg LJP 394 weekly
Number of subjects: 19
Study 11530993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9272319 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin intranasal spray (20 mg)
Number of subjects: 65
Study 9272319 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin intranasal spray (40 mg)
Number of subjects: 65
Study 9272319 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin intranasal spray
Number of subjects: 65
Study 8420877 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia and radiation for superficial tumors
Number of subjects: 208
Study 8420877 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia and radiation for soft tissue sarcomas
Number of subjects: 208
Study 8420877 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia and radiation for deep tumors
Number of subjects: 208
Study 8420877 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia and radiation (general)
Number of subjects: 208
Study 3091196 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay therapy treatment
Number of subjects: 55
Study 3091196 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 55
Study 31652404 — intervention group
Group type: EXPERIMENTAL
Intervention: High fermentable oligo-, di-, monosaccharide, and polyol diet (HFOD)
Number of subjects: 18
Study 31652404 — intervention group
Group type: COMPARATOR
Intervention: Low fermentable oligo-, di-, monosaccharide, and polyol diet (LFOD)
Number of subjects: 18
Study 29380294 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mA cathodal tDCS to the left prefrontal cortex
Number of subjects: 24
Study 29380294 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24
Study 27334883 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative patient education comprising of a video and ICU tour with standard care
Number of subjects: 100
Study 27334883 — intervention group
Group type: COMPARATOR
Intervention: Standard education
Number of subjects: 100
Study 24613349 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept 25 mg
Number of subjects: 255
Study 24613349 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept 75 mg
Number of subjects: 255
Study 24613349 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Number of subjects: 255
Study 24613349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 22844043 — intervention group
Group type: EXPERIMENTAL
Intervention: Resurfacing hip replacement
Number of subjects: 39
Study 22844043 — intervention group
Group type: COMPARATOR
Intervention: Total hip replacement (THR)
Number of subjects: 39
Study 18718884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation using the Neuropsychological Educational Approach to Remediation (NEAR)
Number of subjects: 40
Study 18257181 — intervention group
Group type: EXPERIMENTAL
Intervention: Monkshood cake‐separated mild‐warm moxibustion
Number of subjects: 100
Study 18257181 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Xianling Gubao Capsules
Number of subjects: 100
Study 15926963 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert tele-advice provided to community nurses for 12 weeks
Number of subjects: 0
Study 15926963 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tele-advice)
Number of subjects: 0
Study 12825105 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra) 25, 50, or 100 mg
Number of subjects: 71
Study 10594466 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (MgS) - 12 mmol magnesium lactate daily for 1 month
Number of subjects: 30
Study 10594466 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 30
Study 8734750 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 ppm pacing regimen
Number of subjects: 9
Study 8734750 — intervention group
Group type: COMPARATOR
Intervention: 50 ppm pacing regimen
Number of subjects: 9
Study 8734750 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pacing regimens (80 ppm and 50 ppm)
Number of subjects: 9
Study 2014850 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ritodrine
Number of subjects: 40
Study 2014850 — intervention group
Group type: COMPARATOR
Intervention: Oral indomethacin
Number of subjects: 40
Study 6783519 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite care
Number of subjects: 0
Study 6783519 — intervention group
Group type: COMPARATOR
Intervention: Regular care
Number of subjects: 0
Study 30938842 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (10 mg/day for 1 week, then increasing to 20 mg/day)
Number of subjects: 80
Study 30938842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 30938842 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine and Placebo
Number of subjects: 80
Study 28779916 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean hand acupressure
Number of subjects: 50
Study 28779916 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 26860490 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural analgesia with total intravenous anaesthesia (Group E)
Number of subjects: 60
Study 26860490 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anaesthesia (Group C)
Number of subjects: 60
Study 25618118 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 80
Study 25618118 — intervention group
Group type: COMPARATOR
Intervention: TIVA
Number of subjects: 80
Study 22825227 — intervention group
Group type: EXPERIMENTAL
Intervention: Support of in‐pharmacy HIV testing
Number of subjects: 480
Study 22825227 — intervention group
Group type: EXPERIMENTAL
Intervention: Support of in‐pharmacy vaccinations
Number of subjects: 480
Study 22825227 — intervention group
Group type: EXPERIMENTAL
Intervention: Selling syringes to injection drug users (IDUs)
Number of subjects: 480
Study 19741485 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at rates of 10 to 160 mg . kg(‐1). h(‐1)
Number of subjects: 50
Study 18085142 — intervention group
Group type: EXPERIMENTAL
Intervention: Yuanluo Tongjing needling method
Number of subjects: 60
Study 18085142 — intervention group
Group type: COMPARATOR
Intervention: Aricept, 2.5 mg (oral administration)
Number of subjects: 60
Study 12907440 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVDm (adriamycin, bleomycin, vinblastine, dacarbazine, and methylprednisolone)
Number of subjects: 386
Study 12907440 — intervention group
Group type: COMPARATOR
Intervention: EBVMm (epirubicin, bleomycin, vinblastine, methotrexate, and methylprednisolone)
Number of subjects: 386
Study 12907440 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVDm
Number of subjects: 386
Study 12907440 — intervention group
Group type: COMPARATOR
Intervention: EBVMm
Number of subjects: 386
Study 12364843 — intervention group
Group type: EXPERIMENTAL
Intervention: DVP + quetiapine (450 mg/day)
Number of subjects: 30
Study 12364843 — intervention group
Group type: COMPARATOR
Intervention: DVP + placebo
Number of subjects: 30
Study 9819796 — intervention group
Group type: EXPERIMENTAL
Intervention: R24 monoclonal antibody (0, 5, 25, 50 mg/m2) with IL-2/α-IFN
Number of subjects: 21
Study 9819796 — intervention group
Group type: COMPARATOR
Intervention: IL-2/α-IFN alone
Number of subjects: 21
Study 9819796 — intervention group
Group type: EXPERIMENTAL
Intervention: R24 treatment
Number of subjects: 21
Study 9819796 — intervention group
Group type: COMPARATOR
Intervention: No R24 treatment (control group)
Number of subjects: 21
Study 7814822 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 68
Study 7814822 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 68
Study 2547304 — intervention group
Group type: EXPERIMENTAL
Intervention: AO (doxorubicin and vincristine) alternating with CMC
Number of subjects: 154
Study 2547304 — intervention group
Group type: COMPARATOR
Intervention: AVO (doxorubicin, VP-16, and vincristine) alternating with CMC
Number of subjects: 154
Study 2547304 — intervention group
Group type: EXPERIMENTAL
Intervention: AO/CMC and AVO/CMC
Number of subjects: 154
Study 337773 — intervention group
Group type: EXPERIMENTAL
Intervention: elantrine
Number of subjects: 111
Study 337773 — intervention group
Group type: EXPERIMENTAL
Intervention: elantrine added to L-dopa treatment
Number of subjects: 111
Study 337773 — intervention group
Group type: EXPERIMENTAL
Intervention: elantrine with L-dopa (or Sinemet)
Number of subjects: 111
Study 30506451 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin withdrawal
Number of subjects: 9
Study 30506451 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy after insulin withdrawal
Number of subjects: 9
Study 30506451 — intervention group
Group type: COMPARATOR
Intervention: Insulin-controlled euglycaemia (control)
Number of subjects: 9
Study 28249150 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemolizumab 0.1 mg/kg every 4 weeks
Number of subjects: 264
Study 28249150 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemolizumab 0.5 mg/kg every 4 weeks
Number of subjects: 264
Study 28249150 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemolizumab 2.0 mg/kg every 4 weeks
Number of subjects: 264
Study 28249150 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemolizumab 2.0 mg/kg every 8 weeks
Number of subjects: 264
Study 28249150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 26023905 — intervention group
Group type: EXPERIMENTAL
Intervention: SGA infants
Number of subjects: 1948
Study 26023905 — intervention group
Group type: COMPARATOR
Intervention: AGA infants
Number of subjects: 1948
Study 23988464 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 731
Study 23988464 — intervention group
Group type: COMPARATOR
Intervention: Death certificates
Number of subjects: 731
Study 21195516 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 36
Study 18309155 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone-based antihypertensive regimen
Number of subjects: 4736
Study 18309155 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke during SHEP
Number of subjects: 4736
Study 18309155 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient Ischemic Attack (TIA) during SHEP
Number of subjects: 4736
Study 17176189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohabitation before engagement
Number of subjects: 197
Study 17176189 — intervention group
Group type: COMPARATOR
Intervention: Cohabitation after engagement or not at all
Number of subjects: 197
Study 17176189 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship adjustment and religiousness
Number of subjects: 197
Study 14532798 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic infiltration with 10 ml 1% lidocaine
Number of subjects: 235
Study 14532798 — intervention group
Group type: EXPERIMENTAL
Intervention: Entonox (50% nitrous oxide and oxygen) for 2 minutes
Number of subjects: 235
Study 14532798 — intervention group
Group type: COMPARATOR
Intervention: Control group (no analgesia)
Number of subjects: 235
Study 11281808 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training in music and multimodal stimulation (1 hour instruction)
Number of subjects: 20
Study 11281808 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training in music and multimodal stimulation
Number of subjects: 20
Study 11281808 — intervention group
Group type: COMPARATOR
Intervention: Post-discharge follow-up
Number of subjects: 20
Study 8986487 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous zero‐balanced hemofiltration (HF) without dialysis (ultrafiltrate rate 2 l/h)
Number of subjects: 16
Study 1587033 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingerstall packing
Number of subjects: 0
Study 1587033 — intervention group
Group type: COMPARATOR
Intervention: Merocel packing
Number of subjects: 0
Study 1587033 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone-terramycine gauze packs with ventilation tubes
Number of subjects: 0
Study 1587033 — intervention group
Group type: COMPARATOR
Intervention: Tubes and nasal packing
Number of subjects: 0
Study 1587033 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal patency assessment (peak-flow index and acoustic rhinometry)
Number of subjects: 0
Study 6145024 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 52
Study 6145024 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 52
Study 6145024 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam (in patients with renal failure or gentamicin-resistant isolates)
Number of subjects: 52
Study 31425951 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100 μg or 4000 IU daily for 12 weeks)
Number of subjects: 48
Study 31425951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 27619558 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with gemigliptin 50 mg qd + metformin 1000 to 2000 mg qd
Number of subjects: 433
Study 27619558 — intervention group
Group type: COMPARATOR
Intervention: Gemigliptin monotherapy 50 mg qd
Number of subjects: 433
Study 27619558 — intervention group
Group type: COMPARATOR
Intervention: Metformin monotherapy 1000 to 2000 mg qd
Number of subjects: 433
Study 27343309 — intervention group
Group type: EXPERIMENTAL
Intervention: Antagonist protocol
Number of subjects: 622
Study 24746976 — intervention group
Group type: EXPERIMENTAL
Intervention: ONS-EPA (oral nutritional supplement containing eicosapentaenoic acid)
Number of subjects: 92
Study 24746976 — intervention group
Group type: COMPARATOR
Intervention: Control (isocaloric diet)
Number of subjects: 92
Study 22854909 — intervention group
Group type: EXPERIMENTAL
Intervention: Kambin triangle approach
Number of subjects: 100
Study 22854909 — intervention group
Group type: COMPARATOR
Intervention: Supraneural approach
Number of subjects: 100